The community speaks

Every year, our program includes keynote speeches by some of the top thinkers and trend-makers in pharma, biotech, medtech, digital health, investment & funding, regulatory.

NLSDays features company presentations organised into tracks that interest specific audiences and fields, for example: pharma and biotechnology in R&D, therapeutics or diagnostics, academic and startup innovators, services providers.

Super Sessions address hot topics in science, business development and market strategies.

In between all of these delightful speaking events, we make sure everyone is refreshed by a classic Swedish ‘fika’ – all that your heart desires, plus lots of coffee.

Ms. Niina Aagaard

Chief Operating Officer, Nordic Innovation

20 Apr 11:00 Super Session 1

Dr. Mervi Aavikko

Project Manager FinnGen, University of Helsinki

20 Apr 11:00 Super Session 1

Dr. Ingrid Teigland Akay

Managing Partner, Hadean Ventures

21 Apr 09:15 Super Session 4

Dr. Jacqueline Ameri

CEO, Pancryos

20 Apr 09:30 Opening Plenary

View profile

Dr. Jacqueline Ameri

CEO, Pancryos

Unique Danish funding opportunities for promising and emerging innovations were essential to our early establishment and growth. Likewise, NLSDays is a unique platform that brings together the entire Nordic life science community, not only giving us the possibility of connecting with a relevant VC and Pharma community, but also helping us to establish new partnerships across the Nordic region,

 

PanCryos, a spinout from the Novo Nordisk Foundation Center for Stem Cell Biology at the University of Copenhagen, is devoted to improve the quality of life for the millions of people suffering from type 1 diabetes. The company is developing a best-in-class stem cell derived allogeneic cell therapy (PanINSULA™) that will provide the same glucose control as the pancreatic islet: sensing changes in blood glucose and producing Insulin Naturally. pancryos.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Tina Amini

Medical Device Division Director, NDA Group

19 Apr 10:30 NLS Invest Workshop 1

Ms. Gunilla Andrew-Nielsen

Head of Clinical Trials, Swedish Medical Product Agency

20 Apr 17:30 Workshop E

Dr. Per Antonsson

Investment Manager, Almi Invest

19 Apr 15:30 NLS Invest Workshop 3

Dr. Niccolò Bacchi

Associate, Novo Seeds - Novo Holdings

19 Apr 09:15 NLS Invest Opening

Dr. Sonia Benhamida

Senior Vice President Healthcare, DNB

Ms. Johanna Bergh

European Patent Attorney, Partner, AWA

Mr. Karl Bergman

CEO, Elypta

21 Apr 11:00 Super Session 5

Ms. Frida Björk

European Patent Attorney, Partner, AWA

Dr. Magnus Björsne

CEO, Astrazeneca BioVentureHub

21 Apr 14:00 Super Session 6

Ms. Jeanne Bolger

Corporate Venture Capital Investor, Johnson & Johnson Innovation – JJDC, inc.

21 Apr 09:15 Super Session 4

Dr. Nikolai Brun

Chair HMA-EMA Taskforce on Big Data

20 Apr 11:00 Super Session 1

Mr. Nils Carlin

Director Research & Development, Etvax

20 Apr 15:45 Super Session 3

Dr. Björn Carlsson

Principal Consultant, NDA Group

19 Apr 10:30 NLS Invest Workshop 1

Dr. Dina Chaya

Partner, NeoMed Management - Advisor, Omega Funds

21 Apr 09:15 Super Session 4

Mr. Stephan Christgau

Founding & Managing Partner, Eir Ventures

21 Apr 09:15 Super Session 4

Ms. Karin Conde-Knape

Senior Vice President, Global Drug Discovery, Novo Nordisk

21 Apr 11:00 Super Session 5

Mr. Göran Conradson

Managing Director, Ziccum

20 Apr 15:45 Super Session 3

Dr. Michel de Baar

Executive Director, BD&L, Infectious and Cardiometabolic Diseases, Vaccines & Immunology, MSD

20 Apr 15:45 Super Session 3

Ms. Isabelle de Cremoux

CEO & Managing Partner, Seventure Partners

21 Apr 09:15 Super Session 4

Dr. Eric De La Fortelle

Venture Partner Seventure Partners

20 Apr 14:00 Super Session 2

Mr. Olivier Duchamp

Managing Director, NLSDays - NLS Invest

20 Apr 09:30 Opening Plenary

Mr. Bogi Eliasen

Director of Health, Copenhagen Institute for Futures Studies

20 Apr 11:00 Super Session 1

Dr. Frank Follmann

Director, Vaccine Research, Statens Serum Institut

20 Apr 15:45 Super Session 3

Mr. Erik Gatenholm

CEO and Co-Founder, Cellink

20 Apr 09:30 Opening Plenary

View profile

Mr. Erik Gatenholm

CEO and Co-Founder, Cellink

It’s a great pleasure to speak and network with other entrepreneurs, business leaders, and innovators during the NLSDays 2021. The life science industry is going through a major revolution and what brought us here won’t bring us to the future we want to achieve. In the name of being able to create the future of medicine together, we need to learn to work together, to establish fruitful collaborations – and  that can only be done if we learn to share our stories, ideas, and get to work,

 

In 2016, Cellink commercialized the world’s first universal bioink, the first of many milestones in becoming the world’s leading bioprinting company. In 2020, after 3 successful acquisitions and multiple successful products launched, a bigger idea developed. With the combination of cutting-edge engineering, big data and AI initiatives, and biology, the first bio-convergence company has now emerged. www.cellink.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Jonathan Gertler

Managing Partner & CEO, Back Bay Life Science Advisors - Managing Director, BioVentures Medtech Funds

20 Apr 17:30 Workshop B

Dr. Gianfranco Grompone

Chief Scientific Officer, BioGaia

20 Apr 14:00 Super Session 2

Dr. Abdel Halim

KOL on biomarkers, precision medicine and companion diagnostics, Biomarker Consult

21 Apr 11:00 Super Session 5

Mr. Jonas Hansson

Partner, HealthCap

19 Apr 09:15 NLS Invest Opening

Dr. Deborah Harland

Partner at SR One - GSK Venture Capital Group

21 Apr 09:15 Super Session 4

Dr. Rafiq Hasan

CEO, ExACT Therapeutics

20 Apr 09:30 Opening Plenary

View profile

Dr. Rafiq Hasan

CEO, ExACT Therapeutics

NLSDays 2021 is a great opportunity to learn about the strong innovation emerging from the Nordics, as well as to share experiences and best practices,”

 

EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Ms. Kaisa Helminen

Chief Operating Officer, Aiforia Technologies

20 Apr 09:30 Opening Plenary

View profile

Ms. Kaisa Helminen

Chief Operating Officer, Aiforia Technologies

“As global healthcare systems and organizations are adopting digital technologies such as AI at an ever increasing pace, it is crucial for us as the providers of these transformative solutions to collaborate with each other as well as with the medical professionals adopting these technologies. NLSDays provides that platform for us to share and communicate our vision by bringing together industry leaders across a wide array of fields,”

 

Aiforia’s mission is to provide the most powerful tools for AI-assisted analysis to enhance the translation of medical images into data and discoveries in all realms of healthcare. From scientific research to clinical diagnostics, Aiforia aims to outfit healthcare professionals with the digital solutions they need for the shifting landscape of medicine. www.aiforia.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Renske Hesselink

Senior Consultant Development and Manufacturing, ProPharma Group

20 Apr 15:45 Super Session 3

Mr. Martin Jansson

Senior IP Strategist, AWA

19 Apr 14:00 NLS Invest Workshop 2

Mr. Magnus Jeppsson

Quality Compliance Manager, Baxter International

20 Apr 17:30 Workshop E

Ms. Cathrin Johansson

Communications Manager, AWA

19 Apr 14:00 NLS Invest Workshop 2

Ms. Anneli Jönsson

European Patent Attorney, Partner, AWA

Dr. Karin Kleinhans

Investment Manager, LSP

20 Apr 17:30 Workshop B

Dr. Frederik Knud Nielsen

Strategic Pipeline Lead, Nordics, Novartis

20 Apr 11:00 Super Session 1

Ms. Sarah Lidé

Senior Strategy & Project Manager, Medicon Valley Alliance

20 Apr 14:00 Super Session 2

Mr. Emmanuel Ligner

CEO & President at Cytiva (formerly part of GE Healthcare Life Sciences)

20 Apr 09:30 Opening Plenary

Ms. Lena Lindeberg

Vice President Commercial Operations, LINK Medical Research

21 Apr 16:00 Workshop C

Dr. Lars Lindsköld

Portfolio manager, Sweper / Swelife

20 Apr 11:00 Super Session 1

Mr. Joacim Lydén

European Patent Attorney, Partner, AWA

19 Apr 14:00 NLS Invest Workshop 2

Dr. Joanne M. Hackett

Head of Genomic and Precision Medicine EMEA, IQVIA

21 Apr 09:15 Super Session 4

Ms. Rachel Mears

Deputy Director General, Jeito Capital

21 Apr 09:15 Super Session 4

Dr. Mirjam Mol-Arts

Chief Science and Medical Officer, Ferring Pharmaceuticals

20 Apr 14:00 Super Session 2

Ms. Luisa Monse

Operational Development Manager, Vinnova

21 Apr 17:30 Workshop D

Mr. Søren Møller

Managing Partner, Novo Seeds - Novo Holdings

20 Apr 17:30 Workshop B

Dr. Henrik Bjørn Nielsen

Chief Scientific Officer, Clinical Microbiomics

20 Apr 14:00 Super Session 2

Ms. Sofia Nordgren

Director of Regulatory Affairs, Devicia

21 Apr 14:00 Super Session 6

Dr. Sam Oddsson

Chief Medical Officer & Co-Founder, SidekickHealth

21 Apr 14:00 Super Session 6

Mr. Martin Olovsson

CEO and Co-Founder, Ondosis

21 Apr 14:00 Super Session 6

Dr. Maria Orr

Head of Precision Medicine, Biopharmaceuticals, AstraZeneca

21 Apr 11:00 Super Session 5

Ms. Åsa Otterlund

Partner, Burro Advisors

19 Apr 15:30 NLS Invest Workshop 3

Dr. Helen Pettersson

Investment Manager, Almi Invest

19 Apr 15:30 NLS Invest Workshop 3

Ms. Chelsea Ranger

Program Director NLSDays, SwedenBIO

21 Apr 16:00 Workshop C

20 Apr 09:30 Opening Plenary

Ms. Felicitas Riedl

Life Science Expert, European Investment Bank

21 Apr 09:15 Super Session 4

Ms. Louise Rosenlund Nielsen

Head of International Development & Partnerships, CopCap

20 Apr 11:00 Super Session 1

Dr. Paul Ross

Director, APC Microbiome Ireland

20 Apr 14:00 Super Session 2

Mr. Urban Roth

Client Center Leader Nordic, IBM

21 Apr 14:00 Super Session 6

Dr. Jessica Shull

European Lead, Digital Therapeutics Alliance

21 Apr 14:00 Super Session 6

Mr. Gudmundur Fertram Sigurjonsson

Founder, President & CEO, Kerecis

20 Apr 09:30 Opening Plenary

View profile

Mr. Gudmundur Fertram Sigurjonsson

Founder, President & CEO, Kerecis

It is great to be a part of NLSDays to tell the story of Kerecis and network with other companies in the biotech space. I am now more convinced than ever that the groundbreaking developments that are taking place in the Nordic region truly will make a great impact on our lives,”

 

Residual fish skin has formed the basis of Iceland’s fastest growing company, Kerecis. Skin from cold water fish is naturally rich in Omega-3, which accelerates wound healing and is also ideal for human tissue as there is no risk of infection between such cold-water fish and humans. The company’s vision is to become the world leader in tissue regeneration by sustainably harnessing nature’s own remedies. www.kerecis.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Mr. Leif Rune Skymoen

CEO, Curida

20 Apr 17:30 Workshop E

Dr. Patrick Sobocki

Investment Manager, Industrifonden

21 Apr 11:00 Super Session 5

Dr. Mårten Steen

Partner, HealthCap

20 Apr 17:30 Workshop B

Mr. Edvin Stertman

Intern, Vinnova

21 Apr 17:30 Workshop D

Ms. Helena Strigård

Director General, SwedenBIO

20 Apr 09:30 Opening Plenary

Dr. Helle Friis Svenstrup

Patent Attorney, AWA

19 Apr 14:00 NLS Invest Workshop 2

Dr. Steffen Thirstrup

Director, NDA Regulatory Advisory Board, NDA Advisory Services

19 Apr 10:30 NLS Invest Workshop 1

Dr. Christina Trojel-Hansen

EIR, Arch Venture Partners - Director, Emerson collective, The Steve Jobs family fund

21 Apr 09:15 Super Session 4

Ms. Marit Vaagen

Executive Chairwoman and Founder, Sirona Group

20 Apr 17:30 Workshop E

Ms. Amy VanBuskirk

General Manager, Roche Sweden

20 Apr 11:00 Super Session 1

Dr. Tove Cecilie Viebe

CEO, Seald

21 Apr 11:00 Super Session 5

Ms Marika Vitiä

Investment Manager, Summa Equity

21 Apr 17:30 Workshop D

Mr. Mike Ward

Global Head of Thought Leadership, Decision Resources Group - Clarivate

19 Apr 09:15 NLS Invest Opening

21 Apr 11:00 Super Session 5

Mr. Roland Winger

Senior Vice President Clinical Operations, Allakos

21 Apr 16:00 Workshop C

Prof. Seppo Ylä-Herttuala

Professor, University of Eastern Finland

20 Apr 15:45 Super Session 3